Beximco Pharma launches fifth drug in US market
Francesca Morgan
Company News - 2 mins
10:13, 30th July 2019

Beximco Pharmaceuticals (BXP) FOLLOW, the AIM-listed manufacturer and exporter of medicines in Bangladesh announced on Tuesday that it had officially exported its blood pressure drug, Nadolol, to the US market. 

Alongside its position as a leading exporter of pharmaceuticals in Bangladesh, Beximco has a global footprint in over fifty countries, as well as being accredited across multiple global regulatory authorities -- excluding the US, these include certifications with the EU, Australia, Canada, Taiwan and the Middle East. 

Mr. Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented: "We are delighted to announce the launch of Nadolol, our fifth product in the US market, which demonstrates continued progress in expanding our presence in this important market.”

Nadolol tablets, the company’s fifth product to be launched in the US, are considered the equivalent of Bristol-Myers Squibb's Corgard tablets in its treatment for targeting hypertension and angina pectoris, more commonly referred to as chest pain. According to IQVIA audited data of US market, in 2018 the total market value for Nadolol was more than $63 million.

In August 2016, Beximco Pharma became the first Bangladeshi pharmaceutical company to export medicine to the US market following its manufacturing site approval by the US FDA in June 2015.   

Mr Hassan acknowledged the company’s firm positioning as it continues to establish itself as a leading provider of contemporary medicines across major global markets. He further commented: 

“With a strong portfolio and an attractive pipeline of products in development for the US and other regulated and emerging markets, we are well positioned to continue to achieve double-digit growth in our export business."

For more News and Updates on Beximco Pharmaceuticals: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist